ArticleThe Journal of clinical endocrinology and metabolism2026
IGF-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IGF-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts.The Journal of clinical endocrinology and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
contextAnorexia nervosa (AN) is associated with severe metabolic and endocrine alterations, including growth hormone (GH) resistance and reduced insulin-like growth factor 1 (IGF-1). The longitudinal behavior of IGF-1 during treatment remains incompletely characterized.
objectiveTo evaluate IGF-1 levels in current and weight-restored AN, determine metabolic correlates, and examine longitudinal changes during clinical treatment.
designCross-sectional analysis in a population-based cohort and longitudinal analysis in a clinical cohort.
settingUK Biobank (UKB) and a specialist eating disorder clinic.
participants(1) UKB: 129 adult women with current AN, 2380 weight-restored AN, and 2380 healthy controls (HC) matched for age, sex, and body mass index (BMI). (2) Clinical cohort: 189 adult women with AN assessed at baseline and 12-month follow-up.
main outcome measuresPlasma IGF-1 levels; secondary metabolic and reproductive hormones, including GH, insulin, glucose, free triiodothyronine (FT3), and gonadal hormones.
resultsAcross the UKB groups, IGF-1 levels showed a graded pattern: lowest in current AN, medium in weight-restored AN, and highest in HC. In the clinical cohort, IGF-1 correlated positively with insulin, glucose, and FT3, and negatively with GH, consistent with GH resistance. IGF-1 levels increased significantly over 12 months of treatment (P = .003), with higher BMI at baseline predicting greater increases. Higher IGF-1 levels were associated with a greater likelihood of menstrual function independent of BMI (P < .001).
conclusionIGF-1 appears reduced in current AN and may only partly normalize with weight restoration. IGF-1 may reflect metabolic state and reproductive function, suggesting value as an indicator of severity and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.